Description: Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Home Page: www.precigen.com
PGEN Technical Analysis
20374 Seneca Meadows Parkway
Germantown,
MD
20876
United States
Phone:
301 556 9900
Officers
| Name | Title |
|---|---|
| Mr. Randal J. Kirk J.D. | Exec. Chairman |
| Dr. Helen Sabzevari MPH, Ph.D. | Pres, CEO & Director |
| Mr. Harry Thomasian Jr. | Chief Financial Officer |
| Mr. Donald P. Lehr | Chief Legal Officer & Corp. Sec. |
| Mr. Jeffrey Thomas Perez | Sr. VP of Intellectual Property Affairs |
| Dr. Thomas D. Reed | Founder & Chief Science Officer |
| Mr. Rutul R. Shah | Chief Operating Officer |
| Mr. Steven Harasym | VP & Head of Investor Relations |
| Marie Rossi | VP of Communications |
| Mr. Rob Russell | VP & Head of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2782 |
| Price-to-Sales TTM: | 2.8823 |
| IPO Date: | 2013-08-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 456 |